Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Last week
People
Pharma

Covid-19 roundup: FDA's Stephen Hahn per­son­al­ly helped a doc­tor set up hy­drox­y­chloro­quine tri­al — re­port

Last week
Coronavirus

Stymied by the pan­dem­ic, Im­munomedic­s' new CEO bows out, tak­ing a mil­lion bucks plus perks as he heads out the vir­tu­al ex­it

Last week
People

Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Last week
Deals

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Last week
Bioregnum
R&D

Covid-19 roundup: Buoyed by soar­ing shares, No­vavax inks a $167M deal to buy Covid-19 vac­cine-mak­ing fa­cil­i­ty; France cools on hy­drox­y­chloro­quine

Last week
Coronavirus

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based op­tion

Last week
Pharma
Regulatory

Daphne Koller’s AI start­up gets $143M in new cash from a16z, oth­ers

Last week
Venture
Startups

As biotech IPOs siz­zle on vir­tu­al Wall Street, 3 new play­ers roll the dice on meg­a­money gam­bles top­ping $325M

Last week
IPOs

Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Last week
R&D
Coronavirus

Covid-19 roundup: Jun­shi, Eli Lil­ly ready to launch Covid-19 an­ti­body tri­al; Janet Wood­cock steps aside — for now — as FDA drug czar

Last week
Coronavirus

Af­ter de­cou­pling from Re­gen­eron, Sanofi says it’s time to sell the $13B stake picked up in the mar­riage

Last week
Deals
R&D

An­oth­er NASH de­lay for In­ter­cept frus­trates in­vestors, shares wilt

3 weeks ago
R&D

The man who led Gilead’s au­toim­mune piv­ot heads to Boston; No­var­tis gets a new chief for its AI In­no­va­tion Cen­ter

3 weeks ago
Peer Review

Covid-19 roundup: CanSi­no beats Mod­er­na to pub­li­ca­tion of first-in-hu­man da­ta for a coro­n­avirus vac­cine

3 weeks ago
Coronavirus

A new biotech from a long­time de­vel­op­er wants to bring the tar­get­ed can­cer rev­o­lu­tion to the kids left be­hind

3 weeks ago
R&D

Kad­mon kicks off 're­al-time' NDA sub­mis­sion with an­oth­er look at 're­mark­able' chron­ic graft-ver­sus-host-dis­ease da­ta

3 weeks ago
R&D

Be­zos, Paul Allen funds, a16z put up $100M to build an Il­lu­mi­na of hu­man pro­teins

3 weeks ago
Venture
Startups

Covid-19 roundup: BAR­DA hands As­traZeneca $1B-plus to race through PhI­II and ramp up fall de­liv­er­ies of Ox­ford’s pan­dem­ic vac­cine

3 weeks ago
Coronavirus

Covid-19 roundup: Hit with new con­flict ac­cu­sa­tions, Janet Wood­cock steps out of the agen­cy's Covid-19 chain of com­mand

3 weeks ago
R&D
Coronavirus

Phar­mas­set co-founder jumps in­to Covid-19 fight, with a new com­pa­ny and $215 mil­lion to get there

3 weeks ago
Venture
Coronavirus

An­dreessen Horowitz backs a new mol­e­cule builder from UCLA equipped with the lat­est in con­ver­gence tech. And he’s aim­ing big

3 weeks ago
People
Venture

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

3 weeks ago
Pharma
Regulatory

Al­ly Bridge joins Bain in $120M bet that speed­ing up man­u­fac­tur­ing QC can hit big in post-pan­dem­ic world

3 weeks ago
Venture
Outsourcing
First page Previous page 12345 Next page Last page